Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Weekly Dose-Dense Nanoparticle Paclitaxel (ABI-007), Carboplatin With Herceptin® As First-Line Therapy of Advanced HER-2 Positive Breast Cancer

NCT00093145 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT00093145
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00093145 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Weekly Dose-Dense Nanoparticle Paclitaxel (ABI-007), Carboplatin With Herceptin® As First-Line Therapy of Advanced HER-2 Positive Breast Cancer
Lead sponsor
Celgene
Phase
Phase 2
Overall status
Completed
Start date
June 1, 2004
Completion date
October 1, 2008
Enrollment
32 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer